Right ventricular function in infants with bronchopulmonary dysplasia and pulmonary hypertension: a pilot study

Arabella J Blanca1, Liesbeth Duijts2,3, Esther van Mastrigt2

  • 11 Division of Pediatric Cardiology, Department of Pediatrics, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, The Netherlands.

Pulmonary Circulation
|November 14, 2018
PubMed

Insights

Twelve percent of premature infants with severe bronchopulmonary dysplasia (BPD) showed signs of pulmonary hypertension (PH) at six months. This PH was linked to reduced right ventricular systolic function in these children.

Area of Science:

  • Pediatric Cardiology
  • Neonatology
  • Pulmonary Medicine

Background:

  • Premature birth and bronchopulmonary dysplasia (BPD) are known risk factors for developing pulmonary hypertension (PH) and cardiac changes.
  • It remains unclear if this association between BPD and PH persists beyond early infancy.

Purpose of the Study:

  • To prospectively assess the prevalence of PH in children with severe BPD at six months corrected age.
  • To investigate the impact of BPD and PH on myocardial structure and function at six months corrected age.

Main Methods:

  • Prospective study including preterm infants (gestational age ≤ 32 weeks) with severe BPD.
  • Echocardiography used to diagnose PH and measure left ventricle (LV) and right ventricle (RV) strain via speckle tracking.
  • Evaluated RV fractional area change, RV size, and LV/RV longitudinal and circumferential strain.

Main Results:

  • Eight out of 69 infants (12%) exhibited signs of PH at six months corrected age.
  • Infants with severe BPD and PH showed significantly lower RV fractional area change (35% ± 9% vs. 43% ± 9%) and RV longitudinal systolic strain (-17.6% vs. -20.9%).
  • RV size and LV strain were similar between infants with and without PH.

Conclusions:

  • Pulmonary hypertension is present in 12% of infants with severe BPD at six months corrected age.
  • The presence of PH in this cohort is associated with impaired right ventricular systolic function.
  • Further research is needed to understand the long-term cardiac implications of BPD-associated PH.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
645
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
605
Pulmonary Function Tests01:25

Pulmonary Function Tests

Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
817
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
467
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
509
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
619